Trial Profile
A Randomized, Open-label, Multi-center, Phase 3, 2-arm Study Evaluating the Efficacy and Safety of Peg Interferon Alfa-2b Low-dose Maintenance Monotherapy Versus Standard Supportive Care in Patients With Cirrhotic Hepatitis C Co-infected With Human Immunodeficiency Virus - The ENDURE Study
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms ENDURE
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.; Schering-Plough
- 13 Apr 2019 This trial has been discontinued in belgium, according to European Clinical Trials Database.
- 19 Jun 2007 Status changed from planning to withdrawn prior to recruitment.
- 18 Nov 2006 New trial record.